KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Inventory (2017 - 2025)

Historic Inventory for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $531.7 million.

  • BeOne Medicines' Inventory rose 2316.81% to $531.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $531.7 million, marking a year-over-year increase of 2316.81%. This contributed to the annual value of $495.0 million for FY2024, which is 1895.21% up from last year.
  • As of Q3 2025, BeOne Medicines' Inventory stood at $531.7 million, which was up 2316.81% from $502.9 million recorded in Q2 2025.
  • BeOne Medicines' Inventory's 5-year high stood at $531.7 million during Q3 2025, with a 5-year trough of $73.0 million in Q1 2021.
  • Moreover, its 5-year median value for Inventory was $316.9 million (2023), whereas its average is $334.9 million.
  • Its Inventory has fluctuated over the past 5 years, first soared by 32499.37% in 2021, then skyrocketed by 894.36% in 2023.
  • Over the past 5 years, BeOne Medicines' Inventory (Quarter) stood at $242.6 million in 2021, then increased by 16.37% to $282.3 million in 2022, then skyrocketed by 47.38% to $416.1 million in 2023, then rose by 18.95% to $495.0 million in 2024, then increased by 7.41% to $531.7 million in 2025.
  • Its last three reported values are $531.7 million in Q3 2025, $502.9 million for Q2 2025, and $494.7 million during Q1 2025.